Floatz logo

TIL

Metastatic Ovarian Cancer

Inge Marie SvaneCell therapyPhase 2Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

525 Active assets in the Metastatic Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Carboplatin
Fudan University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Kalinski, Pawel, MD, PhD
Phase 3BB
Inno-206
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

TIL is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →
cancer of unknown primary siteDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →